Abstract
Donor leukocyte infusion (DLI) is recognized as effective therapy for relapse after stem cell transplantation in patients with chronic myelogenous leukemia (CML). However, the clinical efficacy of DLI in the advanced phase of CML or other types of leukemia has not been clearly defined because of its varying degree of success.We describe a 22-year-old male patient with promyelocytic crisis of CML who had a relapse after peripheral blood stem cell transplantation, under reduced-intensity conditioning, from his HLA 2-antigen—mismatched mother. Complete hematologic remission was obtained after transplantation. However, a relapse that occurred on day 66 posttransplantion was characterized by an increase in number of leukemic promyelocytes with simultaneous exacerbation of disseminated intravascular coagulation (DIC).The patient received DLI containing 1 × 107/kg CD3+ cells on day 73. Because rapid improvement of DIC paralleled the decrease in leukemic cells and because it was observed soon after DLI and before the development of acute graft-versus-host disease (GVHD), we hypothesized that leukemia-specific cells other than natural killer cells or cytotoxic T-cells unrelated to GVHD played a role in the graft-versusleukemia effect observed in our patient. In addition, this may be the first report of effective correction of DIC by DLI after stem cell transplantation. Int J Hematol. 2003;77:408-411.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol. 1997;15:433–444.
Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.Blood. 1995;86:2041–2050.
Matsue K, Tabayashi T, Yamada K, Takeuchi M. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Bone Marrow Transplant. 2002;29:63–66.
Keil F, Kalhs P, Haas OA, et al. Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and doseescalating infusion of donor leucocytes.Br J Haematol. 1997;97:161–164.
Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.Blood. 2001;97:2574–2579.
Rosenthal NS, Knapp D, Farhi DC. Promyelocytic blast crisis of chronic myelogenous leukemia: a rare subtype associated with disseminated intravascular coagulation.Am J Clin Pathol. 1995;103:185–188.
Misawa S, Lee E, Scheffer CA, Liu Z, Testa JR. Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blast crisis.Blood. 1986;67:270–274.
Scolnik MP, Palacios MF, Acevedo SH, et al. Promyelocytic blast crisis of chronic myelogenous leukemia with translocations (9;22) and (15;17).Leuk Lymphoma. 1998;31:231–236.
Mitterbauer G, Nemeth P, Wacha S, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction.Br J Haematol. 1999;106:634–43.
Cassinat B, Zassadowski F, Balitrand N, et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR.Leukemia. 2000;14:324–328.
Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.Blood. 1989;73:1720–1728.
Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.Blood. 1995;86:1261–1268.
Moretta A, Moretta L. HLA class I specific inhibitory receptors.Curr Opin Immunol. 1997;9:694–701.
Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.Blood. 1999;94:333–339.
Ruggeri L, Capanni M, Martelli MF, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation.Curr Opin Hematol. 2001;8:355–359.
Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science. 2002;295:2097–2100.
Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma.Blood. 1999;93:2033–2037.
Tamaki S, Ichinohe T, Matsuo K, et al. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts.Bone Marrow Transplant. 2001;28:375–380.
van Rood JJ, Loberiza FR, Jr Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versushost disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.Blood. 2002;99:1572–1577.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Matsue, K., Yamada, K., Takeuchi, M. et al. Rapid Improvement of Disseminated Intravascular Coagulation by Donor Leukocyte Infusions in a Patient with Promyelocytic Crisis of Chronic Myelogenous Leukemia after Reduced-Intensity Stem Cell Transplantation from an HLA 2-Antigen—Mismatched Mother. Int J Hematol 77, 408–411 (2003). https://doi.org/10.1007/BF02982653
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02982653